Literature DB >> 418134

Neutralization of meningococcal endotoxin by antibody to core glycolipid.

C E Davis, E J Ziegler, K F Arnold.   

Abstract

Antibodies to Escherichia coli J5, a uridine 5'-diphosphate-galactose epimerase-less mutant of E. coli 0111, neutralized meningococcal endotoxemia from all three major capsular serogroups. We chose the dermal necrosis of the local Shwartzman phenomenon and the renal cortical necrosis of the general Shwartzman phenomenon as assays because these are the hallmarks of meningococcemia, and because meningococcal lipopolysaccharide (LPS) is a uniquely potent cause of dermal purpura and necrosis. Meningococcal antisera raised against LPS from MGC A, B, and C also provided good protection against endotoxemia from the homologous capsular groups, but it was inconsistent against the heterologous serogroups. The superiority of J5 antibodies (purified IgG as well as antiserum) is probably due to the fact that J5 LPS contains only the endotoxin core. Consequently, immunization with this mutant stimulates production of antibodies to core LPS without interference by the "0" antigenic determinants of the side chains. These observations indicate that the endotoxin core is the toxic moiety of meningococcal LPS, that the core LPS of meningococcus (MGC) is immunologically similar to enteric LPS, and that the antigenically variable "0" side chains of MGC LPS interfere with antibody production against the common core. They also suggest that antibodies prepared against this E. coli mutant could interrupt the devastating course of meningococcal endotoxemia in man, regardless of the capsular serogroup of the infecting strain.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 418134      PMCID: PMC2184252          DOI: 10.1084/jem.147.4.1007

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

2.  Passive immunization against the local Shwartzman reaction.

Authors:  A I Braude; H Douglas
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

3.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

4.  Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin.

Authors:  C E Davis; K R Brown; H Douglas; W J Tate; A I Braude
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

5.  Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

Authors:  E J Ziegler; J A McCutchan; H Douglas; A I Braude
Journal:  Trans Assoc Am Physicians       Date:  1975

6.  Isolation and characterization of a native cell wall complex from Neisseria meningitidis.

Authors:  W D Zollinger; D L Kasper; B J Veltri; M S Artenstein
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

7.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

Authors:  M H Wahdan; F Rizk; A M el-Akkad; A A el-Ghoroury; R Hablas; N I Girgis; A Amer; W Boctar; J E Sippel; E C Gotschlich; R Triau; W R Sanborn; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

8.  Role of meningococcal endotoxin in meningococcal purpura.

Authors:  C E Davis; K Arnold
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

Review 9.  Control of meningococcal meningitis with meningococcal vaccines.

Authors:  M S Artenstein
Journal:  Yale J Biol Med       Date:  1975-07

10.  Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.

Authors:  C E Frasch; L Parkes; R M McNelis; E C Gotschlich
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

View more
  20 in total

Review 1.  The meningococcus and mechanisms of pathogenicity.

Authors:  I W DeVoe
Journal:  Microbiol Rev       Date:  1982-06

2.  The importance of anti-lipid A (anti-endotoxin): prevention of "shock lung" and acute renal failure.

Authors:  E N Wardle
Journal:  World J Surg       Date:  1982-09       Impact factor: 3.352

3.  Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors:  M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

Review 4.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

5.  Immunization against bacteria- and endotoxin-induced hypotension.

Authors:  A M Abdelnoor; A G Johnson; A Anderson-Imbert; A Nowotny
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

6.  Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.

Authors:  B W Fenwick; J S Cullor; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

7.  Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.

Authors:  R W Vreede; J Leuvenink; A S Bouter; E C Brouwer; J H Marcelis; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

8.  Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.

Authors:  D E McCallus; N L Norcross
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

Review 9.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

10.  Neutralization of bacterial lipopolysaccharides by human plasma.

Authors:  H S Warren; T J Novitsky; P A Ketchum; P F Roslansky; S Kania; G R Siber
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.